Literature DB >> 16021677

Co-expression of c-kit and stem cell factor in primary and metastatic nasopharyngeal carcinomas and nasopharyngeal epithelium.

Lai-Fa Sheu1, Wen-Cheng Lee, Herng-Sheng Lee, Woei-Yau Kao, Ann Chen.   

Abstract

Expression of c-kit has been demonstrated in 33% of adult nasopharyngeal carcinomas (NPCs) and in 88% of paediatric NPCs. Patients with tumours expressing c-kit tend to exhibit better survival, but a paracrine/autocrine function for the stem cell factor (SCF)/c-kit system in nasopharyngeal carcinomas has not been reported. This study evaluated the expression of c-kit and SCF by immunohistochemical staining of nasopharyngeal epithelium (NPE) and of primary and metastatic NPCs. In addition, c-kit and SCF expression were studied in HONE-1 NPC cells by immunoprecipitation and western blotting. Expression of c-kit and SCF was detected in 75% and 57% of NPE, respectively, and there was 48% co-expression. In primary NPCs, 86% expressed c-kit, 69% had SCF expression, and there was 67% co-expression. In metastatic NPCs, 76% expressed c-kit, 72% expressed SCF and there was 68% co-expression. Co-expression of c-kit and SCF with tyrosine autophosphorylation of p145(c - kit) was demonstrated in HONE-1 NPC cells. In addition, the expression level of c-kit and its autophosphorylation status was not obviously influenced by the transient co-expression of Epstein-Barr nuclear antigen 1 (EBNA1) and latent membrane protein 1 (LMP1). Co-expression of c-kit and SCF is therefore commonly found in nasopharyngeal epithelium and NPCs, and in HONE-1 NPC cells with autoactivation possibly independent of the co-expression of EBNA1 and LMP1. All of these findings suggest that autoactivation of SCF/c-kit signalling may be a potent regulator of the nasopharyngeal epithelial barrier and of immune function at the nasopharyngeal mucosa surface, and may contribute to the carcinogenesis and progression of NPC. Further molecular analysis is required to evaluate the possibility of treatment with tyrosine kinase inhibitors in NPC, analogous to the treatment of gastrointestinal stromal tumours with STI571. Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16021677     DOI: 10.1002/path.1822

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  10 in total

1.  Changes in c-Kit expression levels during the course of radiation therapy for nasopharyngeal carcinoma.

Authors:  Feng Jiang; Wei Hu; Bicheng Zhang; Jing Xu; Yongjie Shui; Xiaofeng Zhou; Xiaoqiu Ren; Xiaozhong Chen; Li Shen; Qichun Wei
Journal:  Biomed Rep       Date:  2016-09-12

2.  Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.

Authors:  Edwin Pun Hui; Vivian W Y Lui; Cesar S C Wong; Brigette B Y Ma; Cecilia P Y Lau; Crystal S F Cheung; Kakiu Ho; Suk-Hang Cheng; Margaret H L Ng; Anthony T C Chan
Journal:  Invest New Drugs       Date:  2010-05-15       Impact factor: 3.850

3.  Expression of Cancer Stem Cell Biomarkers in Human Head and Neck Carcinomas: a Systematic Review.

Authors:  Raissa Borges Curtarelli; Jussara Maria Gonçalves; Luciane Geanini Pena Dos Santos; Maria Gorete Savi; Jacques Eduardo Nör; Luis André Mendonça Mezzomo; Mabel Mariela Rodríguez Cordeiro
Journal:  Stem Cell Rev Rep       Date:  2018-12       Impact factor: 5.739

Review 4.  Oral epithelial stem cells - implications in normal development and cancer metastasis.

Authors:  Silvana Papagerakis; Giuseppe Pannone; Li Zheng; Imad About; Nawar Taqi; Nghia P T Nguyen; Margarite Matossian; Blake McAlpin; Angela Santoro; Jonathan McHugh; Mark E Prince; Petros Papagerakis
Journal:  Exp Cell Res       Date:  2014-05-05       Impact factor: 3.905

5.  Quantification of Epstein-Barr virus DNA load, interleukin-6, interleukin-10, transforming growth factor-beta1 and stem cell factor in plasma of patients with nasopharyngeal carcinoma.

Authors:  Eng-lai Tan; G Selvaratnam; R Kananathan; Choon-kook Sam
Journal:  BMC Cancer       Date:  2006-09-24       Impact factor: 4.430

6.  Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma.

Authors:  Jian-Wei Zhang; Tao Qin; Shao-Dong Hong; Jing Zhang; Wen-Feng Fang; Yuan-Yuan Zhao; Yun-Peng Yang; Cong Xue; Yan Huang; Hong-Yuan Zhao; Yu-Xiang Ma; Zhi-Huang Hu; Pei-Yu Huang; Li Zhang
Journal:  Chin J Cancer       Date:  2015-04-08

Review 7.  Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.

Authors:  Hengsong Cao; Tian Huang; Mingrui Dai; Xiangyi Kong; Hanyuan Liu; Zhiying Zheng; Guoqiang Sun; Guangshun Sun; Dawei Rong; Zehua Jin; Weiwei Tang; Yongxiang Xia
Journal:  Int J Biol Sci       Date:  2022-08-21       Impact factor: 10.750

8.  Inhibition of Mast Cell-Derived Histamine Decreases Human Cholangiocarcinoma Growth and Differentiation via c-Kit/Stem Cell Factor-Dependent Signaling.

Authors:  Christopher Johnson; Victoria Huynh; Laura Hargrove; Lindsey Kennedy; Allyson Graf-Eaton; Jennifer Owens; Jerome P Trzeciakowski; Kyle Hodges; Sharon DeMorrow; Yuyan Han; Lucas Wong; Gianfranco Alpini; Heather Francis
Journal:  Am J Pathol       Date:  2015-11-18       Impact factor: 4.307

9.  CD117 immunoexpression in canine mast cell tumours: correlations with pathological variables and proliferation markers.

Authors:  Rui M Gil da Costa; Eduarda Matos; Alexandra Rema; Célia Lopes; Maria A Pires; Fátima Gärtner
Journal:  BMC Vet Res       Date:  2007-08-21       Impact factor: 2.741

10.  Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study.

Authors:  Qiuyan Chen; Linquan Tang; Na Liu; Feng Han; Ling Guo; Shanshan Guo; Jianwei Wang; Huai Liu; Yanfang Ye; Lu Zhang; Liting Liu; Pan Wang; Yingqin Li; Qingmei He; Xiaoqun Yang; Qingnan Tang; Yang Li; YuJing Liang; XueSong Sun; Chuanmiao Xie; Yunxian Mo; Ying Guo; Rui Sun; Haoyuan Mo; Kajia Cao; Xiang Guo; Musheng Zeng; Haiqiang Mai; Jun Ma
Journal:  Cancer Commun (Lond)       Date:  2018-11-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.